A Phase 1/2 interventional study of ABX464 150mg and ABX464 50mg in HIV Infections and Health Volunteers, sponsored by Abivax S.A.. Completed at 1 site in Spain. Open to male participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-03-31.
Sponsored by Abivax S.A. · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 261 studies in HIV Infections with a site in Spain — 10 open to participants now, 20 under way, 7 of them phase 3. HIV Infections · Spain.
Among the 261 studies in HIV Infections with a site in Spain, this one is the 169th largest by enrollment of the 229 interventional ones that give a count, is one of 11 that started in 2017, is one of 6 in phase 1/2, and was the 194th registered.
4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.
Browse HIV Infections studies →10 of the 261 studies in HIV Infections with a site in Spain are open now. Recruiting first, the newest first:
Instituto de Investigación Hospital Universitario La Paz · Sites in Spain
Ages 50+
ViiV Healthcare · Sites in Spain, United States, Argentina and 11 more countries
Ages 18+
Casper Rokx · Sites in Spain, Belgium, France and 7 more countries
Ages 18+ · Healthy volunteers
Parc de Salut Mar · Sites in Spain
Ages 18+
Parc de Salut Mar · Sites in Spain
Ages 18+
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.
This study: 18 Years to 65 Years · male · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
261 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 20 · Phase 2 56 · Phase 3 86 · Phase 4 76
First in 1994; this study’s year is marked. 11 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 36 is below the median of 80 across 3,492 interventional studies indexed under HIV Infections.
Median enrollment 99 across the 229 interventional studies, 409 across the 28 observational. Of the 222 that completed or were terminated, 84 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
117 of 261 have an industry lead sponsor. The 10 most frequent:
Abivax S.A. is the lead sponsor of 23 studies on the registry; 2 are open to participants now.
Abivax S.A. has 2 studies filed under HIV Infections — fewer than ten, so there is no comparison to draw.
3 of the studies in HIV Infections with a site in Spain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT00825929Radboud University Medical CenterPharmacokinetics of Antiretroviral Agents in HIV-infected Pregnant Women. | 2026-12 |
| NCT07053384ViiV HealthcareA Study to Investigate the Use of VH3810109 With or Without Fostemsavir (FTR) to Reduce the Size and Activity of the Viral Reservoir in People Living With HIV | 2027-01-22 |
| NCT07202546ViiV HealthcareA Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study) | 2027-10-28 |
Add all 3 to your calendar (.ics) → With an account.
Among the 261 studies in HIV Infections with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of the ABX464-005 study is to characterize the systemic and mucosal immunological sequelae associated with exposure to ABX464 and to explore selected immunological endpoints, compartmental pharmacokinetics, and pharmacodynamics.
The purpose of the ABX464-005 study is to characterize the systemic and mucosal immunological sequelae associated with exposure to ABX464 and to explore selected immunological endpoints, compartmental pharmacokinetics, and pharmacodynamics. The site will screen and enroll 12 HIV-infected subjects who will receive 150 mg ABX464 orally once daily for 28 days (Cohort 1). Following completion of this cohort a further 24 subjects will be enrolled: 12 HIV-uninfected subjects will receive 50 mg ABX464 orally once daily for 28 days (Cohort 2) and 12 HIV-infected subjects (Cohort 3) who will 50 mg ABX464 orally once daily for 84 days.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For positive Subjects
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ABX464, 50mg per Capsule Three Capsules per day for 28 days
Drug: ABX464 150mg
ABX464, 50mg per Capsule One Capsule per day for 28 days
Drug: ABX464 50mg
ABX464, 50mg per Capsule One Capsule per day for 84 days
Drug: ABX464 50mg
ABX464 given orally at 150 mg per day from Day 0 to Day 28 (Cohort 1/ HIV infected subjects)
ABX464 given orally at 50 mg per day from Day 0 to Day 28 (Cohort 2 / non HIV infected subjects)
ABX464 given orally at 50 mg per day from Day 0 to Day 84 (Cohort 3 / HIV infected subjects)
Area Under the Curve (AUC) of ABX464 in Sera
Pharmacokinetic parameters
Time frame: Day 1, Day 28 and Day 84
Maximum Observed Concentration (Cmax) of ABX464 in Sera
Pharmacokinetic parameters
Time frame: Day 1, Day 28 and day 84
Area Under the Curve (AUC) of ABX464 Metabolite (ABX464-N-Glucuronide) in Sera
Pharmacokinetics parameters
Time frame: Day 1, Day 28 and Day 84
Maximum Observed Concentration (Cmax) of ABX464 Metabolite (ABX464-N-Glucuronide) in Sera
Pharmacokinetic parameters
Time frame: Day 1, Day 28 and Day 84
Maximum Observed Concentration (Cmax) of ABX464 in Peripheral Blood Mononuclear Cells (PBMC)
Pharmacokinetic parameters
Time frame: Day 1, Day 28 and Day 84
Area Under the Curve (AUC) of ABX464 in Peripheral Blood Mononuclear Cells (PBMC)
Pharmacokinetic parameters
Time frame: Day 1, Day 28 and Day 84
Maximum Observed Concentration (Cmax) of ABX464 Metabolite (ABX464-N-Glucuronide) in Peripheral Blood Mononuclear Cells (PBMC)
Pharmacokinetic parameters
Time frame: Day 1, Day 28 and Day 84
Area Under the Curve (AUC) of ABX464 Metabolite (ABX464-N-Glucuronide) in Peripheral Blood Mononuclear Cells (PBMC)
Pharmacokinetic parameters
Time frame: Day 1, Day 28 and Day 84
Concentration of ABX464 in Rectal Tissue (Measured Only at Pre-infusion Timepoint)
Pharmacokinetic parameters
Time frame: Day 1, Day 28, Day 56, Day 84 and Day 112
Concentration of ABX464 Metabolite (ABX464-N-Glucuronide) in Rectal Tissue (Measured Only at Pre-infusion Timepoint)
Pharmacokinetic parameters
Time frame: Day 1, Day 28, Day 56, Day 84 and Day 112
Mean Change From Baseline in Plasma Viral Load (Ultrasensitive Assay)
Viral Load Assessments (HIV-1 RNA copies/ml)
Time frame: Day 28, Day 56, Day 84 and Day 112
CD4+ Counts (Cell/mm^3)
T-cell determinations
Time frame: Day 28, Day 35, Day 56, Day 84, Day 91 and Day 112
Total HIV-1 DNA Reservoir in Peripheral Blood Mononuclear Cells (PBMC)
HIV reservoir cells (CD4+)
Time frame: Day 28, Day 56, Day 84 and Day 112
| Milestone | ABX464 150mg | ABX464 50mg for 28 Days | ABX464 50mg for 84 Days |
|---|---|---|---|
| Started | 11 | 12 | 13 |
| Completed | 11 | 12 | 13 |
| Not completed | 0 | 0 | 0 |
Pharmacokinetic parameters
| ng*h/mL | ABX464 150mg | ABX464 50mg for 28 Days | ABX464 50mg for 84 Days |
|---|---|---|---|
| Day 1 | 306.0 ± 46.5 | 63.7 ± 39.9 | 63.7 ± 77.4 |
| Day 28 | 119.8 ± 48.7 | 17.8 ± 60.9 | 30.3 ± 68.2 |
| Day 84 | — | — | 28.9 ± 66.8 |
Pharmacokinetic parameters
| ng/mL | ABX464 150mg | ABX464 50mg for 28 Days | ABX464 50mg for 84 Days |
|---|---|---|---|
| Day 1 | 106.1 ± 54.5 | 23.1 ± 45.2 | 24.5 ± 75.5 |
| Day 28 | 50.9 ± 57.1 | 9.3 ± 60.3 | 13.0 ± 76.0 |
| Day 84 | — | — | 15.6 ± 65.6 |
Pharmacokinetics parameters
| ng*h/mL | ABX461 150mg | ABX464 50mg for 28 Days | ABX464 50mg for 84 Days |
|---|---|---|---|
| Day 1 | 50115.8 ± 41.5 | 8282.3 ± 37.0 | 11209.6 ± 66.5 |
| Day 28 | 48605.0 ± 40.6 | 4800.6 ± 37.0 | 13308.8 ± 62.5 |
| Day 84 | — | — | 14588.2 ± 58.3 |
Pharmacokinetic parameters
| ng/mL | ABX464 150mg | ABX464 50mg for 28 Days | ABX464 50mg for 84 Days |
|---|---|---|---|
| Day 1 | 9918.2 ± 33.5 | 1626.8 ± 36.9 | 2036.2 ± 62.8 |
| Day 28 | 7011.1 ± 37.5 | 695.9 ± 38.6 | 1705.5 ± 71.8 |
| Day 84 | — | — | 2150.6 ± 56.1 |
Pharmacokinetic parameters
| ng/mL | ABX464 150mg | ABX464 50mg for 28 Days | ABX464 50mg for 84 Days |
|---|---|---|---|
| Day 1 | 463.3 ± 55.0 | 209.4 ± 54.4 | 203.8 ± 81.0 |
| Day 28 | 247.8 ± 75.7 | 76.4 ± 51.7 | 72.3 ± 82.9 |
| Day 84 | — | — | 73.6 ± 57.5 |
Pharmacokinetic parameters
| ng*h/mL | ABX464 150mg | ABX464 50mg for 28 Days | ABX464 50mg for 84 Days |
|---|---|---|---|
| Day 1 | 1120.7 ± 52.6 | 594.2 ± 53.2 | 481.5 ± 78.9 |
| Day 28 | 522.4 ± 49.2 | 156.0 ± 51.8 | 151.6 ± 74.3 |
| Day 84 | — | — | 144.9 ± 48.6 |
Pharmacokinetic parameters
| ng/mL | ABX464 150mg | ABX464 50mg for 28 Days | ABX464 50mg for 84 Days |
|---|---|---|---|
| Day 1 | 585.5 ± 60.3 | 39.7 ± 90.5 | 230.0 ± 153.9 |
| Day 28 | 491.5 ± 73.0 | 35.6 ± 85.7 | 125.1 ± 86.1 |
| Day 84 | — | — | 153.3 ± 49.4 |
Pharmacokinetic parameters
| ng*h/mL | ABX464 150mg | ABX464 50mg for 28 Days | ABX464 50mg for 84 Days |
|---|---|---|---|
| Day 1 | 2133.7 ± 42.2 | 39.2 ± 186.7 | 835.3 ± 116.0 |
| Day 28 | 2212.3 ± 58.8 | 35.0 ± 210.1 | 697.5 ± 92.0 |
| Day 84 | — | — | 766.5 ± 57.4 |
Pharmacokinetic parameters
| ng/mL | ABX464 150mg | ABX464 50mg for 28 Days | ABX464 50mg for 84 Days |
|---|---|---|---|
| Day 1 | 0.0 ± 0.00 | 0.0 ± 0.00 | 0.0 ± 0.00 |
| Day 28 | 0.1 ± 0.11 | 0.1 ± 0.19 | 0.1 ± 0.13 |
| Day 56 | 0.0 ± 0.00 | — | — |
| Day 84 | — | — | 0.1 ± 0.13 |
| Day 112 | — | — | 0.0 ± 0.00 |
Pharmacokinetic parameters
| ng/mL | ABX464 150mg | ABX464 50mg for 28 Days | ABX464 50mg for 84 Days |
|---|---|---|---|
| Day 1 | 0.0 ± 0.00 | 0.1 ± 0.08 | 0.0 ± 0.00 |
| Day 28 | 0.1 ± 0.04 | 0.1 ± 0.11 | 0.1 ± 0.09 |
| Day 56 | 0.0 ± 0.00 | — | — |
| Day 84 | — | — | 0.2 ± 0.11 |
| Day 112 | — | — | 0.0 ± 0.00 |
Viral Load Assessments (HIV-1 RNA copies/ml)
| copies/mL | ABX464 150mg | ABX464 50mg |
|---|---|---|
| Day 28 | -0.9 (-1.9 to 0.1) | -2.0 (-4.3 to 0.2) |
| Day 56 | -0.4 (-1.5 to 0.7) | — |
| Day 84 | — | -0.9 (-3.0 to 1.2) |
| Day 112 | — | -1.1 (-3.7 to 1.5) |
T-cell determinations
| cells/mm^3 | ABX464 150mg | ABX464 50mg |
|---|---|---|
| Day 28 | -130.6 (-217.5 to -43.6) | -34.6 (-167.7 to 98.5) |
| Day 35 | -125.6 (-266.2 to 15.1) | — |
| Day 56 | 29.6 (-202.4 to 261.5) | — |
| Day 84 | — | 8.3 (-90.2 to 106.9) |
| Day 91 | — | 23.3 (-122.5 to 169.0) |
| Day 112 | — | 161.8 (59.5 to 264.2) |
HIV reservoir cells (CD4+)
| copies/10^6 cells | ABX464 150mg | ABX464 50mg |
|---|---|---|
| Day 28 | -86.8 (-172.2 to -1.3) | 22.3 (-21.7 to 66.4) |
| Day 56 | -37.1 (-139.1 to 64.9) | — |
| Day 84 | — | 10.8 (-55.3 to 76.9) |
| Day 112 | — | 95.6 (26.1 to 165.0) |
Collected over From baseline up to 112 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| ABX464 150mg | 0/11 (0%) | 0/11 (0%) | 9/11 (81.8%) |
| ABX464 50mg for 28 Days | 0/12 (0%) | 0/12 (0%) | 3/12 (25%) |
| ABX464 50mg for 84 Days | 0/13 (0%) | 0/13 (0%) | 7/13 (53.8%) |
| Event | ABX464 150mg | ABX464 50mg for 28 Days | ABX464 50mg for 84 Days |
|---|---|---|---|
| HeadacheNervous system disorders | 8/11 | 2/12 | 4/13 |
| Back painMusculoskeletal and connective tissue disorders | 4/11 | 0/12 | 1/13 |
| MyalgiaMusculoskeletal and connective tissue disorders | 4/11 | 0/12 | 0/13 |
| NauseaGastrointestinal disorders | 4/11 | 0/12 | 0/13 |
| Abdominal painGastrointestinal disorders | 2/11 | 0/12 | 2/13 |
| DiarrhoeaGastrointestinal disorders | 1/11 | 0/12 | 2/13 |
| AsthemiaGeneral disorders | 1/11 | 0/12 | 0/13 |
| HyperamylasaemiaMetabolism and nutrition disorders | 1/11 | 0/12 | 0/13 |
| HyperlipaseamiaMetabolism and nutrition disorders | 1/11 | 0/12 | 0/13 |
| InsomniaPsychiatric disorders | 1/11 | 0/12 | 0/13 |
| Age, Categorical(Participants) | ABX464 150 mg Capsules for 28 Days | ABX464 50 mg Capsules for 28 Days | ABX464 50 mg Capsules for 84 Days | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 11 | 12 | 13 | 36 |
| >=65 years | 0 | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | ABX464 150 mg Capsules for 28 Days | ABX464 50 mg Capsules for 28 Days | ABX464 50 mg Capsules for 84 Days | Total |
|---|---|---|---|---|
| Female | 0 | 0 | 0 | 0 |
| Male | 11 | 12 | 13 | 36 |
| Race (NIH/OMB)(Participants) | ABX464 150 mg Capsules for 28 Days | ABX464 50 mg Capsules for 28 Days | ABX464 50 mg Capsules for 84 Days | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 |
| White | 11 | 12 | 13 | 36 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | ABX464 150 mg Capsules for 28 Days | ABX464 50 mg Capsules for 28 Days | ABX464 50 mg Capsules for 84 Days | Total |
|---|---|---|---|---|
| Spain | 11 | 12 | 13 | 36 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Mar 2017 to primary completion in Dec 2018, 21 months.
Results were first posted in Mar 2023, 4 years 3 months after primary completion.
Of 42 phase 1/2 interventional studies under HIV Infections, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 73. This study's 21 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: ABX464